Press Releases

Date	Title	View
05/11/20	Summary Toggle U.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of Life	PDF Version
05/06/20	Summary Toggle Horizon Therapeutics plc Reports Strong First-Quarter 2020 Financial Results; Increasing TEPEZZA™ Full-Year 2020 Net Sales Guidance to Greater Than $200 Million Due to Rapid Uptake; Increasing Full-Year 2020 Net Sales Guidance	Q1 2020 Earnings Release 384.3 KB
04/27/20	Summary Toggle Horizon Therapeutics plc Announces Availability of PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets in the United States	PDF Version
04/15/20	Summary Toggle Horizon Therapeutics plc to Release First-Quarter 2020 Financial Results and Host Webcast on May 6, 2020	PDF Version
04/09/20	Summary Toggle Horizon Therapeutics plc Named One of the 2020 Best Workplaces in Health Care and Biopharma by Fortune and Great Place to Work®	PDF Version
04/02/20	Summary Toggle Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline	Press Release 194.3 KB
03/31/20	Summary Toggle TEPEZZA™ (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes	PDF Version
03/26/20	Summary Toggle Horizon Therapeutics plc Donates $1.5 Million to COVID-19 Response Efforts in Illinois and Other Impacted U.S. and Global Communities	PDF Version
03/03/20	Summary Toggle Horizon Therapeutics plc Launches the Down and Out Kidney Campaign to Call Attention to the Prevalence and Impact of Gout in Chronic Kidney Disease	PDF Version
02/28/20	Summary Toggle Horizon and Willis Tower Elevate the Need for Rare Disease Innovation on Rare Disease Day	PDF Version